Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...
Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a ...
IN BRIEF Joint ventures have been a popular vehicle for businesses to work together to share competencies and knowledge to ...
Shares of Replimune Group receive multiple downgrades after the Food and Drug Administration twice rejects its experimental ...
Chitosan-based materials have emerged as a vital area in nanobiotechnology, bridging advances in materials science with pressing needs in both biomedical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results